Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Integrated digital error suppression for improved detection of circulating tumor DNA.
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW, Shrager JB, Loo BW Jr, Neal JW, Wakelee HA, Diehn M, Alizadeh AA. Newman AM, et al. Nat Biotechnol. 2016 May;34(5):547-555. doi: 10.1038/nbt.3520. Epub 2016 Mar 28. Nat Biotechnol. 2016. PMID: 27018799 Free PMC article.
High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate personalized cancer therapy. ...To overcome these limitations, we introduce an approach for integrated digital error suppression (iDES). Our method …
High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate personalized cancer therapy. ...To o …
Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection.
Sumbal S, Javed A, Afroze B, Zulfiqar HF, Javed F, Noreen S, Ijaz B. Sumbal S, et al. Exp Hematol. 2018 Sep;65:17-28. doi: 10.1016/j.exphem.2018.06.003. Epub 2018 Jun 23. Exp Hematol. 2018. PMID: 29940219 Review.
Fortunately, these restrictions have been overcome by technological advancements allowing us to track both genetic and epigenetic aberrations. Cell-free circulating tumor DNA (ctDNA) analysis, or "liquid biopsy" from a blood sample, provides the opportunity t …
Fortunately, these restrictions have been overcome by technological advancements allowing us to track both genetic and epigenetic aberration …